AvidBiotics split creates two biotechs in hot areas – BioPharma Dive
|
AvidBiotics split creates two biotechs in hot areas
BioPharma Dive Last month, following a patient death, the Food and Drug Administration put a clinical hold on two Phase 1 studies of Cellectis' gene-edited allogeneic CAR–T therapy, UCART123, in acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. |
